Retatrutide

Retatrutide 20mg, 12mg or 6mg — Research Compound

• Many researchers start with a dose of 1mg-2mg per week.
• Target dosing of 4mg-5mg per week.

Retatrutide is a multi-receptor peptide agonist targeting GLP-1, GIP, and glucagon receptors, developed for the treatment of obesity and type 2 diabetes.

By simultaneously modulating these three pathways, Retatrutide provides a comprehensive metabolic approach, promoting weight loss, glycemic control, improved lipid metabolism, and enhanced energy expenditure. Its once- weekly subcutaneous administration improves patient adherence while maintaining therapeutic efficacy.

Mechanism of Action:
– GLP-1 receptor activation: Stimulates glucose- dependent insulin secretion, suppresses appetite, and improves glycemic control.
– GIP receptor activation: Enhances insulin response and supports fat metabolism.
– Glucagon receptor activation: Increases energy expenditure and promotes fatty acid oxidation.
– Synergistic effects: Dual and triple receptor engagement provides superior weight loss, cardiometabolic benefits, and metabolic flexibility compared to single-agent therapies.

Benefits May Include:

• Weight Loss: Up to 24% body weight reduction in clinical trials; targets visceral fat
• Glycemic Control: HbA1c reduction up to 2.2%; improves glucose homeostasis and insulin sensitivity
• Energy Expenditure: Promotes thermogenesis and fatty acid oxidation through glucagon receptor activity
• Appetite Regulation: Enhanced satiety and reduced caloric intake via GLP-1 and GIP pathways
• Cardiovascular Health: Reduces triglycerides, improves lipid profile, lowers systolic blood pressure
• Fat Loss & Body Composition: Preferential visceral fat reduction; maintains lean mass
• Metabolic Flexibility: Optimizes glucose and lipid metabolism for overall metabolic health
• Sustained Efficacy: Once-weekly dosing supports long- term adherence and durable metabolic effects

Specifications:

• Compound: Retatrutide 12mg or 20mg
• Format: Research compound
• Use: Research use only